Stockreport

VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement 

VYNE Therapeutics Inc.  (VYNE) 
PDF Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) anti [Read more]